JPWO2020150716A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020150716A5 JPWO2020150716A5 JP2021541712A JP2021541712A JPWO2020150716A5 JP WO2020150716 A5 JPWO2020150716 A5 JP WO2020150716A5 JP 2021541712 A JP2021541712 A JP 2021541712A JP 2021541712 A JP2021541712 A JP 2021541712A JP WO2020150716 A5 JPWO2020150716 A5 JP WO2020150716A5
- Authority
- JP
- Japan
- Prior art keywords
- enpp1
- viral vector
- enpp3
- signal peptide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025027352A JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794450P | 2019-01-18 | 2019-01-18 | |
| US62/794,450 | 2019-01-18 | ||
| US201962821692P | 2019-03-21 | 2019-03-21 | |
| US62/821,692 | 2019-03-21 | ||
| US201962877044P | 2019-07-22 | 2019-07-22 | |
| US62/877,044 | 2019-07-22 | ||
| PCT/US2020/014296 WO2020150716A1 (en) | 2019-01-18 | 2020-01-20 | Treatment of diseases involving deficiency of enpp1 or enpp3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025027352A Division JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517435A JP2022517435A (ja) | 2022-03-08 |
| JPWO2020150716A5 true JPWO2020150716A5 (https=) | 2023-01-31 |
| JP2022517435A5 JP2022517435A5 (https=) | 2023-01-31 |
| JP7724156B2 JP7724156B2 (ja) | 2025-08-15 |
Family
ID=71613451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541712A Active JP7724156B2 (ja) | 2019-01-18 | 2020-01-20 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
| JP2025027352A Pending JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025027352A Pending JP2025084821A (ja) | 2019-01-18 | 2025-02-21 | Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210187067A1 (https=) |
| EP (1) | EP3911153A4 (https=) |
| JP (2) | JP7724156B2 (https=) |
| KR (1) | KR20210142599A (https=) |
| CN (1) | CN113631033B (https=) |
| AU (1) | AU2020207967A1 (https=) |
| BR (1) | BR112021013941A2 (https=) |
| CA (1) | CA3126839A1 (https=) |
| IL (1) | IL284699A (https=) |
| MX (1) | MX2021008503A (https=) |
| WO (1) | WO2020150716A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076848A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
| AU2021383830A1 (en) * | 2020-11-19 | 2023-06-22 | Biomarin Pharmaceutical Inc. | Treatment of enpp1 deficiency and abcc6 deficiency |
| WO2023049864A1 (en) * | 2021-09-24 | 2023-03-30 | Inozyme Pharma, Inc. | Lyophilized enpp1 polypeptide formulations and uses thereof |
| KR20240167914A (ko) * | 2022-04-04 | 2024-11-28 | 이노자임 파마, 인코포레이티드 | Enpp1 결핍증 및 abcc6 결핍증의 치료 |
| WO2025213139A1 (en) * | 2024-04-04 | 2025-10-09 | The General Hospital Corporation | Enpp1 gene therapy for the treatment of vascular disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6894022B1 (en) * | 1998-08-27 | 2005-05-17 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| CA2462653C (en) * | 2001-11-07 | 2016-06-07 | Aya Jakobovits | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| EP1736553A1 (en) * | 2005-06-17 | 2006-12-27 | Centre National De La Recherche Scientifique | ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
| US8168586B1 (en) * | 2007-11-21 | 2012-05-01 | Celera Corporation | Cancer targets and uses thereof |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| EP3470089A1 (en) * | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| CA2960912A1 (en) * | 2014-09-16 | 2016-03-24 | Universitat Autonoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| EP3234116B1 (en) * | 2014-12-19 | 2021-09-08 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
| KR20250078598A (ko) * | 2015-05-19 | 2025-06-02 | 예일 유니버시티 | 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법 |
| BR112019002355A2 (pt) * | 2016-08-05 | 2019-07-16 | Yale University | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme |
| EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
-
2020
- 2020-01-20 KR KR1020217025330A patent/KR20210142599A/ko not_active Ceased
- 2020-01-20 CA CA3126839A patent/CA3126839A1/en active Pending
- 2020-01-20 JP JP2021541712A patent/JP7724156B2/ja active Active
- 2020-01-20 WO PCT/US2020/014296 patent/WO2020150716A1/en not_active Ceased
- 2020-01-20 CN CN202080009084.9A patent/CN113631033B/zh active Active
- 2020-01-20 EP EP20741209.9A patent/EP3911153A4/en active Pending
- 2020-01-20 MX MX2021008503A patent/MX2021008503A/es unknown
- 2020-01-20 AU AU2020207967A patent/AU2020207967A1/en active Pending
- 2020-01-20 BR BR112021013941-9A patent/BR112021013941A2/pt unknown
-
2021
- 2021-02-17 US US17/178,127 patent/US20210187067A1/en not_active Abandoned
- 2021-07-08 IL IL284699A patent/IL284699A/en unknown
-
2022
- 2022-08-25 US US17/822,245 patent/US20230031809A1/en active Pending
-
2025
- 2025-02-21 JP JP2025027352A patent/JP2025084821A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025039615A (ja) | 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法 | |
| CN113316639A (zh) | 用于治疗庞贝氏病的治疗性腺相关病毒 | |
| TW202023630A (zh) | 核酸分子及其用於非病毒基因療法的用途 | |
| JP7654562B2 (ja) | 線維芽細胞増殖因子２３関連低リン血症性疾患の遺伝子療法 | |
| KR20220160052A (ko) | 분할 인테인 및 그 용도 | |
| KR20210126029A (ko) | 체액성 면역을 회피하기 위한 조성물 및 방법 | |
| RS61305B1 (sr) | Preparati i metode mutantskog faktora viii | |
| WO2024255448A1 (zh) | 凝血因子fviii蛋白变体、表达载体和用途 | |
| CN109952114A (zh) | 用于治疗醛脱氢酶缺乏的基因疗法 | |
| JPWO2020150716A5 (https=) | ||
| US20180163229A1 (en) | Novel recombinant adeno-associated virus capsids containing a designed ankyrin repeat protein (darpin) or fragment thereof | |
| CN116829595A (zh) | 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送 | |
| TW202214849A (zh) | 可溶性enpp1蛋白質及其用途 | |
| JP7576039B2 (ja) | 第ｉｘ因子バリアントおよび治療でのその使用 | |
| WO2022094157A1 (en) | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof | |
| JP2025538873A (ja) | 発現の改善と治療への使用のために操作されたｄｎａｓｅ１－ｌｉｋｅ３ | |
| TW202417633A (zh) | 用於眼適應症之載體化抗TNF-α抑制劑 | |
| RU2021120107A (ru) | Лечение заболеваний, включающих дефицит enpp1 или enpp3 | |
| US12583907B2 (en) | Modified plasma clotting factor VIII and method of use thereof | |
| WO2026057767A1 (en) | Use of split intein for the treatment of abca3-associated disease | |
| WO2021078834A1 (en) | Chimeric acid-alpha glucosidase polypeptides and uses thereof | |
| RU2815545C2 (ru) | Генная терапия гипофосфатемических заболеваний, связанных с фактором роста фибробластов 23 | |
| JPWO2022076848A5 (https=) | ||
| EP4314041A1 (en) | Modified plasma clotting factor viii and method of use thereof | |
| HK40059690A (en) | Therapeutic adeno-associated virus for treating pompe disease |